Lipocine Inc. (NASDAQ:LPCN) experienced a sharp market response Thursday after the company disclosed that its investigational oral brexanolone candidate, LPCN 1154, did not achieve the primary efficacy endpoint in a phase 3 trial for postpartum depression.
The randomized study enrolled 90 patients with postpartum depression. The trial's prespecified primary endpoint was the change from baseline in the 17-item Hamilton Depression Rating Scale (HAM-D17) total score at hour 60 versus placebo. LPCN 1154 did not produce a statistically significant reduction in HAM-D17 total score compared with placebo at that time point.
Within the data, Lipocine reported a post hoc analysis focusing on a subset of 54 trial participants who had a history of psychiatric conditions. In that subgroup, LPCN 1154 produced nominally statistically significant and what the company described as clinically meaningful reductions in HAM-D scores compared with placebo as early as hour 12, with effects sustained through day 30. The placebo-adjusted difference in HAM-D was -7.2 at hour 12 and -5.3 at day 30 in this post hoc cohort.
On safety, Lipocine said LPCN 1154 was generally well tolerated across the overall study population. No adverse event, including somnolence or dizziness, was reported in more than 5% of LPCN 1154-treated participants. The company reported no treatment-related severe or serious adverse events and no instances of excessive sedation or loss of consciousness.
Following the post hoc findings, Lipocine has applied for breakthrough therapy and fast track designations for LPCN 1154 in patients with postpartum depression. The company also indicated plans to conserve capital and to engage with stakeholders to review potential paths forward. Those options may include continued development of LPCN 1154, advancing other product candidates, pursuing strategic transactions, forming partnerships, or considering other opportunities.
Lipocine said it will complete a full analysis of the phase 3 data in the coming weeks and intends to present the trial results at upcoming scientific conferences.
Context for markets and stakeholders
The phase 3 outcome triggered a steep decline in Lipocine's share price, reflecting investor reassessment of the program's near-term prospects. The company is signaling that it will weigh regulatory engagement, potential designation requests, and a range of strategic options while it finalizes its internal analyses.